Baxter International Inc (BAX) Shares Bought by Linscomb & Williams Inc.

Share on StockTwits

Linscomb & Williams Inc. boosted its stake in shares of Baxter International Inc (NYSE:BAX) by 0.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,772 shares of the medical instruments supplier’s stock after buying an additional 147 shares during the quarter. Linscomb & Williams Inc.’s holdings in Baxter International were worth $1,282,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc lifted its position in shares of Baxter International by 1.3% during the third quarter. Vanguard Group Inc now owns 36,398,931 shares of the medical instruments supplier’s stock worth $2,805,993,000 after purchasing an additional 470,198 shares in the last quarter. Northern Trust Corp lifted its position in shares of Baxter International by 1.6% during the fourth quarter. Northern Trust Corp now owns 8,615,513 shares of the medical instruments supplier’s stock worth $567,073,000 after purchasing an additional 136,476 shares in the last quarter. Norges Bank acquired a new stake in shares of Baxter International during the fourth quarter worth about $549,458,000. Veritas Asset Management LLP lifted its position in shares of Baxter International by 1.0% during the first quarter. Veritas Asset Management LLP now owns 7,850,949 shares of the medical instruments supplier’s stock worth $638,361,000 after purchasing an additional 77,608 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Baxter International by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 6,444,204 shares of the medical instruments supplier’s stock worth $423,409,000 after purchasing an additional 297,006 shares in the last quarter. 84.39% of the stock is owned by institutional investors.

Shares of NYSE:BAX opened at $75.10 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.30 and a current ratio of 1.83. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $82.25. The company has a market capitalization of $38.31 billion, a P/E ratio of 24.62, a PEG ratio of 1.77 and a beta of 0.96.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.08. The company had revenue of $2.63 billion for the quarter, compared to analysts’ expectations of $2.61 billion. Baxter International had a net margin of 14.27% and a return on equity of 20.04%. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter last year, the company earned $0.70 earnings per share. As a group, analysts predict that Baxter International Inc will post 3.32 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Friday, June 7th will be given a dividend of $0.22 per share. The ex-dividend date is Thursday, June 6th. This is a positive change from Baxter International’s previous quarterly dividend of $0.19. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.17%. Baxter International’s dividend payout ratio (DPR) is 24.92%.

Several analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Monday, May 20th. JPMorgan Chase & Co. increased their price target on shares of Baxter International from $80.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, May 13th. Wells Fargo & Co increased their price target on shares of Baxter International from $80.00 to $89.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 3rd. Cowen set a $75.00 price target on shares of Baxter International and gave the stock a “hold” rating in a research report on Monday, April 22nd. Finally, Barclays increased their price target on shares of Baxter International from $72.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Monday, April 15th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $78.33.

In other news, Director Thomas T. Stallkamp sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $75.16, for a total transaction of $75,160.00. Following the transaction, the director now directly owns 6,780 shares in the company, valued at $509,584.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Third Point Llc sold 5,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $76.37, for a total transaction of $381,850,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,057,187 shares of company stock worth $386,297,619. Insiders own 0.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Baxter International Inc (BAX) Shares Bought by Linscomb & Williams Inc.” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://weekherald.com/2019/05/26/baxter-international-inc-bax-shares-bought-by-linscomb-williams-inc.html.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: Buy-Side Analysts

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.